3rd Quarter - Report

MEHLMAN CONSULTING, INC. for VIZIENT INC

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues. 340B Drug Pricing Program. S. 1895, No Surprises Act. H.R.3 - Lower Drug Costs Now Act of 2019. S.2543 - Prescription Drug Pricing Reduction Act of 2019

LobbyistCovered position, as disclosed
LAUREN ARONSON New Dir., Office of Legis., CMS; Professional Staff Member, Cmte on Ways & Means; Policy Dir., White House; Policy Dir., HHS Office of Health Reform (detailed to the White House); Policy Advisor, (Rep. R. Emanuel); Health LA, (Rep. C. McCarthy)
DEAN ROSEN —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1895 (116th), S. 2543 (116th), H.R. 3 (116th)

Medicare/Medicaid MMM

Healthcare transparency, costs and access to affordable medication and other healthcare items and services.

LobbyistCovered position, as disclosed
DEAN ROSEN —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.